RT @drteplinsky
19/22 #TumorBoardTuesday #BreastCancer
🔥Bonus🔥Mini tweetorial
✨TROPICS-02✨

📌 Results
🎉OS 14.4 mo vs 11.2 mo (HR 0.79)

📍subgroup analysis from #ESMO22 shows improvement in PFS similar in HER2-low and HER2 IHC 0 subgroups

👍🏽Great option for HER2 low disease

RT @Drteplinsky
19/22 #TumorBoardTuesday #BreastCancer
🔥Bonus🔥Mini tweetorial
✨TROPICS-02✨

📌 Results
🎉OS 14.4 mo vs 11.2 mo (HR 0.79)

📍subgroup analysis from #ESMO22 shows improvement in PFS similar in HER2-low and HER2 IHC 0 subgroups

👍🏽Great option for HER2 low disease

RT @DrChoueiri@twitter.com

12/ Some history behind this project: it started when several of our mentees led by @sarahaboualaiwi@twitter.com teamed up to organize a database of “genomics + phenomics”, then by luck (Thanks @vivek_naranbhai@twitter.com !), we met @fairfax@twitter.com lab (Live during #ESMO22) and converged on the same story 👇

🐦🔗: https://twitter.com/DrChoueiri/status/1603817707874443264

RT @pashtoonkasi: 🆕 Just published @NatureMedicine @Nature

Editorial on✍🏽
#LiquidBiopsies & the Tumor Mutational Burden cutoff conundrum.

🩸Blood-TMB or plasma-TMB cutoffs need to be harmonized; across platforms, & tissue🆚 liquid.

💡Thoughts?

#ESMO22
https://t.co/kCNQXsWvmy https://t.co/7PSeRahcjK

@oncology